Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.

R&D Spending: Viatris vs Arrowhead - A Decade of Innovation

__timestampArrowhead Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 201423138050581800000
Thursday, January 1, 201557410147671900000
Friday, January 1, 201641454452876700000
Sunday, January 1, 201731690298857900000
Monday, January 1, 201852968505822200000
Tuesday, January 1, 201981048686778200000
Wednesday, January 1, 2020128874979512600000
Friday, January 1, 2021206342000681000000
Saturday, January 1, 2022297307000662200000
Sunday, January 1, 2023353188000910700000
Monday, January 1, 2024505870000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Innovators: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Viatris Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D investments.

From 2014 to 2023, Viatris consistently allocated a significant portion of its resources to R&D, peaking in 2023 with a 56% increase from its 2014 expenditure. Meanwhile, Arrowhead Pharmaceuticals showcased a remarkable growth story, with its R&D expenses surging by over 2,000% during the same period. This dramatic rise underscores Arrowhead's aggressive push towards pioneering new treatments.

Interestingly, the data for 2024 reveals a gap for Viatris, suggesting a potential shift in strategy or reporting. As these companies forge ahead, their R&D investments will undoubtedly shape the future of healthcare innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025